Literature DB >> 26457856

Drugs in Breast Milk.

Edward R Newton1, Thomas W Hale.   

Abstract

Most drugs appear in breast milk in very small and safe amounts. The obstetric care provider evaluates drug transfer most commonly in the peripartum period, postpartum hospitalization; and they are often consulted when the new mother has a subsequent need for drug therapy. The chapter provides the foundations for the safest decisions for the mother and her breastfed infant. The foundation of safe decisions is accomplished through a review of the physiology of lactation, the lactation pharmacology, and the specific pharmacology and infant safety of drugs common to everyday obstetric practice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26457856     DOI: 10.1097/GRF.0000000000000142

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  14 in total

Review 1.  Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.

Authors:  Ariela Frieder; Madeleine Fersh; Rachel Hainline; Kristina M Deligiannidis
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 2.  Outcomes of Children with Fetal and Lactation Immunosuppression Exposure Born to Female Transplant Recipients.

Authors:  Cameron J McKinzie; Jillian P Casale; Jack C Guerci; Alyson Prom; Christina T Doligalski
Journal:  Paediatr Drugs       Date:  2022-07-23       Impact factor: 3.930

Review 3.  Evaluation of the Safety of Drugs and Biological Products Used During Lactation: Workshop Summary.

Authors:  J Wang; T Johnson; L Sahin; M S Tassinari; P O Anderson; T E Baker; C Bucci-Rechtweg; G J Burckart; C D Chambers; T W Hale; D Johnson-Lyles; R M Nelson; C Nguyen; D Pica-Branco; Z Ren; H Sachs; J Sauberan; A Zajicek; S Ito; L P Yao
Journal:  Clin Pharmacol Ther       Date:  2017-06       Impact factor: 6.875

Review 4.  Psychoactive drug exposure during breastfeeding: a critical need for preclinical behavioral testing.

Authors:  Irving Zucker
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

Review 5.  Pharmacotherapy for depression and bipolar disorder during lactation: A framework to aid decision making.

Authors:  Jennifer Sprague; Katherine L Wisner; Debra L Bogen
Journal:  Semin Perinatol       Date:  2020-01-30       Impact factor: 3.300

6.  Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes.

Authors:  Andrea Ines Ciplea; Annette Langer-Gould; Anna Stahl; Sandra Thiel; Annette Queisser-Wahrendorf; Ralf Gold; Kerstin Hellwig
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-20

7.  Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder.

Authors:  Andrea Ines Ciplea; Annette Langer-Gould; Annick de Vries; Tiny Schaap; Sandra Thiel; Marius Ringelstein; Ralf Gold; Kerstin Hellwig
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-04-23

8.  Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation.

Authors:  Undine Proschmann; Rocco Haase; Hernan Inojosa; Katja Akgün; Tjalf Ziemssen
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

Review 9.  Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.

Authors:  Jolien J M Freriksen; Minou van Seyen; Ali Judd; Diana M Gibb; Intira J Collins; Rick Greupink; Frans G M Russel; Joost P H Drenth; Angela Colbers; David M Burger
Journal:  Aliment Pharmacol Ther       Date:  2019-08-25       Impact factor: 8.171

10.  The Effectiveness and Safety of Intravenous Dexmedetomidine of Different Concentrations Combined with Butorphanol for Post-Caesarean Section Analgesia: A Randomized Controlled Trial.

Authors:  Shijiang Liu; Peipei Peng; Youli Hu; Cunming Liu; Xiaofei Cao; Chun Yang; Mei Gao
Journal:  Drug Des Devel Ther       Date:  2021-02-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.